Prices delayed by at least 15 minutes | Print


Renalytix PLC (RENX)

ORD 0.25P
Sell: 34p|Buy: 36p|Change: 0.50 (-1.43%)

Open 

35p


Previous close 

35p


Trade high 

34.7p


Volume 

29,166


Year high 

150.00p


Year low 

10.00p


Dividend yield 

-


Market capitalisation 

£41.37 mn


P/E ratio 

-


ISIN 

GB00BYWL4Y04


This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment

Share price

Performance 27/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Renalytix PLC 0.00
FTSE AIM All Share+ 0.35
More...

Company profile

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Sector 

Healthcare


News

Recent trades

DateTimePriceQuantityValue (£)
28/03/202411:36:3234.55,0001,725.00
28/03/202411:36:1234.53,7331,287.89
28/03/202411:08:0134.5800276.00
28/03/202410:08:0534.541,447499.79
28/03/202409:12:5534.058,6412,942.26

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.